Alexion takes its first step rebuilding the pipeline, adding a rare disease drug in $855M cash buyout
Biotech buyouts are all the rage these days. Today, it’s Alexion’s $ALXN turn to score with a deal that adds a Phase III drug for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
